Official Title
Treatment of Dravet Syndrome With Fenfluramine (Expanded Access Protocol)
Brief Summary

The purpose of this research study is to (1) provide access to fenfluramine for patientswith intractable epilepsy associated with Dravet syndrome, and (2) evaluate the safety offenfluramine.

Detailed Description

The purpose of this research study is to (1) provide access to fenfluramine for patients
with intractable epilepsy associated with Dravet syndrome, and (2) evaluate the safety of
fenfluramine.

Available
Treatment IND/Protocol
Dravet Syndrome

Drug: Fenfluramine

The treatment plan for this Expanded Access Protocol is for patients with Dravet syndrome
who do not qualify for participation in one of the ongoing ZX008 (fenfluramine
hydrochloride) clinical trials.
Other Name: Fenfluramine Hydrochloride

Eligibility Criteria

Inclusion Criteria:

- Genetic diagnosis of Dravet syndrome with intractable seizures despite failing all
available medications for seizures.

Eligibility Gender
All
Eligibility Age
Minimum: 2 Years ~ Maximum: N/A
Countries
United States
Locations

University of California, Los Angeles
Los Angeles, California, United States

Investigator: Shaun Hussain, MD
Contact: 310-206-4037

Contacts

Angela Martinez
310-206-4037
angelamartinez@mednet.ucla.edu

Not Provided

University of California, Los Angeles
NCT Number
MeSH Terms
Epilepsies, Myoclonic
Syndrome
Fenfluramine